China-based Inmagene Biopharmaceuticals has announced the first patient dosing in a global, multi-center, proof-of-concept study assessing the safety, pharmacokinetics, and efficacy of its pipeline candidate IMG-007. The molecule is being evaluated as a treatment for moderate-to-severe atopic dermatitis (AD), a condition that affects a significant patient population worldwide.
IMG-007: An Ultra-Long Half-Life Antagonistic Monoclonal Antibody
IMG-007 is an antagonistic monoclonal antibody (mAb) targeting OX40, featuring an ultra-long half-life and no antibody-dependent cell-mediated cytotoxicity (ADCC) effect due to the bioengineering modification of its Fc region. This unique characteristic was demonstrated in a single dose dosage escalation study in healthy adults, where IMG-007’s half-life exceeded the average half-life of traditional IgG antibodies.
Inmagene’s Pipeline and Development Focus
Inmagene, a clinical-stage biotech company focused on immunology and inflammatory diseases, has four drug candidates under development. Lead compound IMG-007, a unique OX40 mAb, is undergoing two global Phase II studies. Additionally, the company’s BTK inhibitor IMG-004 is nearing completion of Phase I trials. IMG-008, an IL-36R mAb, is entering a global Phase I study. Finally, IMG-020 (izokibep), an anti-IL-17 protein drug, is undergoing global clinical development for five indications, showcasing Inmagene’s broad pipeline and commitment to advancing treatments for immunological and inflammatory conditions.-Fineline Info & Tech
